How I Treat Paroxysmal Nocturnal Hemoglobinuria
In this point-counterpoint digital activity, two expert faculty discuss and debate treatment selection for patients with PNH through case-based scenarios. Faculty review mechanisms of action, clinical trial data, and real-world evidence supporting divergent treatment strategies for the presented cases. How do the experts make their initial treatment selections? Why might they choose a C5 inhibitor or a C3 inhibitor? How do they assess response to treatment, and what do they do when treatment response is suboptimal? View the activity and find out!
Faculty: Jamile Shammo, MD, FASCP, FACP & Carlos de Castro, MD
Expiration Date: June 30, 2024